Q3 beat; sales guidance narrowed upwards; incoming CEO could shift gears
04/11/26 -"BioNTech’s Q3 operational performance exceeded expectations, driven by higher outlicensing sales from Bristol-Myers Squibb. 2026 sales guidance was narrowed and the midpoint raised. While most recent ..."
Pages
56
Language
English
Published on
04/11/26
You may also be interested by these reports :
12/11/26
The Q3 results exceeded consensus estimates, backed by the strong showing of Electronics (driven by demand from AI applications) and healthy support ...
11/11/26
The Q3 profitability materially surpassed expectations, backed by the strong momentum for migraine and depression/schizophrenia treatments. The ...
06/11/26
Genmab’s sales missed expectations, but profitability significantly exceeded expectations. Growth was driven by contributions from most offerings, ...
06/11/26
Sanofi’s growth in recent years has been single-handedly driven by its cornerstone immunology treatment Dupixent, though there has been some support ...